NCT01220661

Brief Summary

In colorectal surgery, the use of prophylactic antibiotics is recommended. The standard use of antibiotics for colorectal surgery is three doses. It has been reported that the surgical site infection rates of laparoscopic colorectal surgery are lower than open colorectal surgery. However, the evidence of proper application of antibiotic for laparoscopic colorectal surgery is still not enough. The investigators are researching the efficacy and safety of one dose prophylactic antibiotic in laparoscopic colorectal surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
312

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Oct 2010

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

October 12, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 14, 2010

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

December 13, 2011

Status Verified

December 1, 2011

Enrollment Period

1.2 years

First QC Date

October 12, 2010

Last Update Submit

December 11, 2011

Conditions

Keywords

Colorectal SurgerySurgical Wound InfectionLaparoscopyAnti-Bacterial Agents

Outcome Measures

Primary Outcomes (1)

  • Surgical site infection

    any surgical infections (superficial incisional infection or infection of deep incision space or organ space infection)

    Three weeks after surgery

Secondary Outcomes (1)

  • Overall infection

    Three weeks after surgery

Study Arms (1)

One dose

EXPERIMENTAL

One dose prophylactic antibiotic

Drug: Cefotetan

Interventions

preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)

Also known as: Yamatetan
One dose

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients have laparoscopic colorectal surgery for cancer at National Cancer Center
  • Patients should sign a written informed consent
  • Age between 18-80 years
  • Adequate bone marrow function Hb ≥ 10g/dl (after treatment for simple iron deficiency anemia) WBC ≥ 3,000/mm3 PLT ≥ 100,000/mm3
  • Adequate kidney function Creatinine ≤ 1.5 mg/dl
  • No remarkable evidence of heart dysfunction and lung dysfunction

You may not qualify if:

  • Patients undergo emergency surgery with multiple symptoms
  • Open colorectal surgery for cancer or conversion to an open procedure
  • Patients who undergo only ostomy surgery
  • Palliative surgery
  • Surgery combined with other organs
  • Patients on treatment with recurred cancer
  • Patients who have active bacterial infection and required parenteral antibiotics
  • Patients have an allergy to Cefoxitin
  • Other organ cancer history(except who had radical excision for skin cancer)
  • Presence of other serious disease
  • Mentally ill patients
  • Legally unable to participate in clinical trial
  • Lactating or pregnant women
  • Patients who will obviously fail to regular follow-up visit or will be off study voluntarily
  • Not eligible to participate for other reasons by doctor's decision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Cancer Center Hospital

Goyang-si, Gyeonggi-do, 410-769, South Korea

Location

MeSH Terms

Conditions

Surgical Wound Infection

Interventions

Cefotetan

Condition Hierarchy (Ancestors)

Wound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CephamycinsCephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsTetrazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Jae Hwan Oh

    Center for Colorectal Cancer, National Cancer Center Korea

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D.

Study Record Dates

First Submitted

October 12, 2010

First Posted

October 14, 2010

Study Start

October 1, 2010

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

December 13, 2011

Record last verified: 2011-12

Locations